MILESTONE MEDICAL : PROVIDES THE UPDATE ON COMMERCIAL ROLLOUT OF COMPUFLO® EPIDURAL SYSTEM IN Q1 2021

Contact:

David Waldman or Justyna Gudaszewska

Crescendo Communications, LLC

Email: [e-mail]

Tel: [phone] / + 1 561 453 0406

Milestone Medical Provides the Update on Commercial Rollout of

Compuflo® Epidural System in Q1 2021

Roseland, NJ, May 17, 2021 - Milestone Medical Inc. (WAR:MMD) today provided injections, today provided a business update for the first quarter ended March 31, 2021.

Leonard Osser, Interim Chief Executive Officer of Milestone Medical Inc., stated, "Our primary focus has been, and continues to be, the commercialization of the CompuFlo Epidural System. Specifically, now that we have penetrated several medical institutions with our CompuFlo® Epidural Instrument and CathCheck™ System, we are aggressively building our sales and marketing organization as we prepare for the next phase of our growth. We believe these latest commercial orders from several recognized hospitals is validation that the technology provides a level of safety and efficiency not currently available to medical professionals using conventional syringes. We truly believe 2021 will be a transformative year for our medical business and an important turning point as Milestone Scientific Inc., the parent of the Company ("MLSS") and the Company execute on joint goal of establishing the medical instruments and disposables as the new standard of care for epidural procedures in labor and delivery."

Leonard Osser further noted, "The strong balance sheet of MLSS with approximately $17 million of cash and cash equivalents as of March 31, 2021 provides us substantial resources and the ability to accelerate our sales and marketing activities around both our medical instruments. It also allows MLSS and the Company to advance the development and commercialization of other indications for our proprietary DPS Dynamic Pressure Sensing Technology, which we believe represent further growth opportunities for our company. Additionally, last week we announced the appointment of Arjan Haverhals as CEO of the Company effective May 19, 2021 and hired Scott Kahn as new CFO. Arjan has already proven his exceptional leadership as President of MLSS, and Scott will be instrumental, not only overseeing our financial infrastructure, but also helping us to increase investor awareness as we execute on key milestones. I look forward to playing a counsel role in the further growth and success of the Company."

About Milestone Medical Inc.

Milestone Medical, Inc. (WAR:MMD) has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrument in the U.S. Milestone Medical received

CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next- generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

# # #